We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Actelion will have to get FDA approval of a risk evaluation and mitigation strategy (REMS) for Tracleer before the agency approves the drug’s sNDA, which seeks an expanded indication to treat patients with less severe pulmonary arterial hypertension (PAH).